Drug intelligence / Profile preview

alemtuzumab + hydroxyurea

Development stage: Unknown
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination of alemtuzumab, a humanized monoclonal antibody targeting CD52 on lymphocytes, and hydroxyurea, a cytotoxic agent that increases fetal hemoglobin production. When combined, these drugs may increase the risk of adverse effects due to their overlapping immunosuppressive and myelosuppressive properties.

Targets

CD52 (CD52 Antigen)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on alemtuzumab + hydroxyurea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alemtuzumab + hydroxyurea.

Explore the full profile